IL262124A - t cell receptors - Google Patents

t cell receptors

Info

Publication number
IL262124A
IL262124A IL262124A IL26212418A IL262124A IL 262124 A IL262124 A IL 262124A IL 262124 A IL262124 A IL 262124A IL 26212418 A IL26212418 A IL 26212418A IL 262124 A IL262124 A IL 262124A
Authority
IL
Israel
Prior art keywords
cell receptors
receptors
cell
Prior art date
Application number
IL262124A
Other languages
Hebrew (he)
Original Assignee
Adaptimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58536983&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL262124(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adaptimmune Ltd filed Critical Adaptimmune Ltd
Publication of IL262124A publication Critical patent/IL262124A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL262124A 2016-04-08 2018-10-04 t cell receptors IL262124A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201606156 2016-04-08
PCT/EP2017/058578 WO2017174823A1 (en) 2016-04-08 2017-04-10 T cell receptors

Publications (1)

Publication Number Publication Date
IL262124A true IL262124A (en) 2018-11-29

Family

ID=58536983

Family Applications (1)

Application Number Title Priority Date Filing Date
IL262124A IL262124A (en) 2016-04-08 2018-10-04 t cell receptors

Country Status (15)

Country Link
US (3) US20190144521A1 (en)
EP (2) EP3925972A1 (en)
JP (2) JP7204484B2 (en)
KR (1) KR20190065189A (en)
CN (2) CN116239669A (en)
AU (2) AU2017248121B2 (en)
BR (1) BR112018070637A2 (en)
CA (1) CA3020555A1 (en)
ES (1) ES2788188T5 (en)
IL (1) IL262124A (en)
MX (1) MX389173B (en)
RU (1) RU2018138837A (en)
SG (1) SG11201808750PA (en)
WO (1) WO2017174823A1 (en)
ZA (1) ZA201806862B (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211754T1 (en) 2014-12-23 2022-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
ES2991142T3 (en) * 2016-04-08 2024-12-02 Adaptimmune Ltd T cell receptors
HRP20211493T1 (en) 2016-04-08 2022-01-21 Adaptimmune Limited T STATION RECEPTORS
CN116239669A (en) * 2016-04-08 2023-06-09 艾达普特免疫有限公司 T cell receptor
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf Chimeric antigen receptors
US20210041435A1 (en) * 2018-01-31 2021-02-11 Tohoku University Method for regulating antigen-specific mhc expression
CA3097399A1 (en) 2018-04-19 2019-10-24 The Board Of Regents, The University Of Texas System T cell receptors with mage-b2 specificity and uses thereof
GB201819540D0 (en) * 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
CN110172091B (en) * 2019-04-28 2020-04-03 天津亨佳生物科技发展有限公司 Specific T cell receptor aiming at EGFR L858R gene mutation and application thereof
EP3986938A4 (en) * 2019-06-18 2023-06-28 Regeneron Pharmaceuticals, Inc. Mage-a4 t cell receptors and methods of use thereof
MX2021015452A (en) 2019-06-25 2022-02-11 Gilead Sciences Inc FLT3L-FC FUSION PROTEINS AND METHODS OF USE.
US12480958B2 (en) 2019-08-13 2025-11-25 Immatics Biotechnologies Gmbh Method for the characterization of peptide:MHC binding polypeptides
US20230000913A1 (en) 2019-08-13 2023-01-05 King's College London Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the il-1 superfamily
IL295023A (en) 2020-02-14 2022-09-01 Jounce Therapeutics Inc Antibodies and fusion proteins that bind to ccr8 and uses thereof
EP4153633A1 (en) 2020-05-19 2023-03-29 Amgen Inc. Mageb2 binding constructs
CN111647069B (en) * 2020-06-17 2022-06-21 深圳豪石生物科技有限公司 Improved TCR and application thereof
TW202406932A (en) 2020-10-22 2024-02-16 美商基利科學股份有限公司 Interleukin-2-fc fusion proteins and methods of use
WO2022140321A2 (en) * 2020-12-22 2022-06-30 Amgen Inc. Mage-b2-specific t-cell receptors
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
EP4304726A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Mage-a4 peptide-mhc antigen binding proteins
TW202313094A (en) 2021-05-18 2023-04-01 美商基利科學股份有限公司 Methods of using flt3l-fc fusion proteins
JP2024539252A (en) 2021-10-28 2024-10-28 ギリアード サイエンシーズ， インコーポレイテッド Pyridin-3(2H)-one derivatives
CA3235986A1 (en) 2021-10-29 2023-05-04 Gilead Science, Inc. Cd73 compounds
EP4452414A2 (en) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
EP4667056A1 (en) 2021-12-22 2025-12-24 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (en) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7 inhibitors
LT4245756T (en) 2022-03-17 2024-11-25 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN116836261A (en) * 2022-03-24 2023-10-03 香雪生命科学技术（广东）有限公司 High-affinity TCR (TCR) for recognizing MAGE-A4 antigen, and sequence and application thereof
US20230374036A1 (en) 2022-04-21 2023-11-23 Gilead Sciences, Inc. Kras g12d modulating compounds
CN117106060A (en) * 2022-05-17 2023-11-24 香雪生命科学技术（广东）有限公司 A high-affinity T cell receptor that recognizes MAGE and its application
IL317958A (en) 2022-07-01 2025-02-01 Gilead Sciences Inc Cd73 compounds
US12161673B2 (en) 2022-09-14 2024-12-10 Cdr-Life Ag MAGE-A4 peptide dual T cell engagers
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
EP4695260A1 (en) 2023-04-11 2026-02-18 Gilead Sciences, Inc. Kras modulating compounds
KR20250175331A (en) 2023-04-21 2025-12-16 길리애드 사이언시즈, 인코포레이티드 PRMT5 inhibitors and uses thereof
AU2024306338A1 (en) 2023-06-30 2026-01-08 Gilead Sciences, Inc. Kras modulating compounds
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
AU2024300557A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
TW202506719A (en) * 2023-07-27 2025-02-16 德商艾瑪提克生物技術有限公司 Antigen binding proteins against mageb2
WO2025021979A1 (en) * 2023-07-27 2025-01-30 Immatics Biotechnologies Gmbh Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026039365A1 (en) 2024-08-12 2026-02-19 Gilead Sciences, Inc. Kras modulating compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596536B1 (en) * 1991-02-08 2003-07-22 Aventis Pharma S.A. Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
EP1117679B9 (en) 1998-10-02 2010-07-07 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
US6407063B1 (en) 1998-10-02 2002-06-18 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
US20050053918A1 (en) 2001-05-16 2005-03-10 Technion Research & Development Foundation Ltd. Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses
US6867283B2 (en) * 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
EP1421115B1 (en) 2001-08-31 2005-03-02 Avidex Limited Soluble t cell receptor
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances
WO2010114129A1 (en) * 2009-04-03 2010-10-07 国立大学法人愛媛大学 T cell receptor and nucleic acid encoding the receptor
PT2440575E (en) 2009-06-09 2015-02-12 Vaxon Biotech Identification, optimization and use of shared hla-b*0702 epitopes for immunotherapy
BR112013006718B1 (en) 2010-09-20 2021-12-07 Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberguniversität Mainz Gemeinnutzige Gmbh NY-ESO-1 SPECIFIC T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND USE THEREOF
KR20140108520A (en) * 2011-10-14 2014-09-11 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 ANTIBODIES TO CD1d
CN105431524B (en) * 2013-06-10 2020-04-21 达娜-法勃肿瘤研究所公司 Methods and compositions for reducing immunosuppression of tumor cells
JP6255360B2 (en) 2015-03-04 2017-12-27 ヴァクソン バイオテックＶａｘｏｎ Ｂｉｏｔｅｃｈ Identification, optimization and use of immunotherapy for shared HLA-B * 0702 epitopes
ES2914648T3 (en) 2016-04-08 2022-06-15 Immunocore Ltd T cell receptors
HRP20211493T1 (en) 2016-04-08 2022-01-21 Adaptimmune Limited T STATION RECEPTORS
CN116239669A (en) 2016-04-08 2023-06-09 艾达普特免疫有限公司 T cell receptor
ES2991142T3 (en) 2016-04-08 2024-12-02 Adaptimmune Ltd T cell receptors

Also Published As

Publication number Publication date
JP2022122913A (en) 2022-08-23
AU2017248121B2 (en) 2022-07-21
JP2019516356A (en) 2019-06-20
ES2788188T3 (en) 2020-10-20
EP3440104B1 (en) 2020-03-11
JP7572399B2 (en) 2024-10-23
US11753456B2 (en) 2023-09-12
AU2022256182A1 (en) 2022-11-24
BR112018070637A2 (en) 2019-02-05
ES2788188T5 (en) 2023-10-24
WO2017174823A1 (en) 2017-10-12
RU2018138837A3 (en) 2020-07-30
NZ747962A (en) 2024-12-20
US20220025013A1 (en) 2022-01-27
AU2017248121A1 (en) 2018-11-22
SG11201808750PA (en) 2018-11-29
MX389173B (en) 2025-03-20
WO2017174823A4 (en) 2017-12-07
JP7204484B2 (en) 2023-01-16
US20240010702A1 (en) 2024-01-11
CN116239669A (en) 2023-06-09
US12180261B2 (en) 2024-12-31
EP3440104A1 (en) 2019-02-13
EP3440104B2 (en) 2023-06-14
CA3020555A1 (en) 2017-10-12
KR20190065189A (en) 2019-06-11
EP3925972A1 (en) 2021-12-22
CN109476724A (en) 2019-03-15
US20190144521A1 (en) 2019-05-16
ZA201806862B (en) 2021-04-28
CN109476724B (en) 2023-04-04
MX2018012268A (en) 2019-02-07
RU2018138837A (en) 2020-05-12

Similar Documents

Publication Publication Date Title
IL271435A (en) t cell receptors
IL262128A (en) t cell receptors
IL262124A (en) t cell receptors
IL262146A (en) t cell receptors
HUE059159T2 (en) T cell receptors
DK3448882T3 (en) ANTI-KK-LC-1-T CELL RECEPTORS
IL251524A0 (en) t cell receptors
IL264425B1 (en) Anti-kras-g12d t cell receptors
EP3858365C0 (en) GOLD-OPTIMIZED CAR-T CELLS
IL252258B (en) K-R-EST anti-mutation cell receptors
HUE046262T2 (en) Cell
PL3547392T3 (en) BATTERY
LT3433270T (en) T CELL RECEPTORS
EP3613123A4 (en) EFFICIENCY-BASED BATTERY CONFIGURATIONS
UA34266S (en) BATTERY
UA35362S (en) BATTERY
UA35581S (en) BATTERY
UA35580S (en) BATTERY
UA35361S (en) BATTERY
UA33587S (en) BATTERY
UA33154S (en) BATTERY
UA32500S (en) BATTERY
UA32499S (en) BATTERY
UA33381S (en) BATTERY
FI20155610A7 (en) Cell element